CN110694056B - 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 - Google Patents
一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 Download PDFInfo
- Publication number
- CN110694056B CN110694056B CN201911023197.XA CN201911023197A CN110694056B CN 110694056 B CN110694056 B CN 110694056B CN 201911023197 A CN201911023197 A CN 201911023197A CN 110694056 B CN110694056 B CN 110694056B
- Authority
- CN
- China
- Prior art keywords
- fsh
- amino acid
- antigen
- carrier protein
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 42
- 102000036639 antigens Human genes 0.000 title claims abstract description 42
- 108091007433 antigens Proteins 0.000 title claims abstract description 42
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 230000008878 coupling Effects 0.000 claims abstract description 24
- 238000010168 coupling process Methods 0.000 claims abstract description 24
- 238000005859 coupling reaction Methods 0.000 claims abstract description 24
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 21
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 108010038807 Oligopeptides Proteins 0.000 claims description 21
- 102000015636 Oligopeptides Human genes 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- -1 6-dioxanylidene Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 238000001308 synthesis method Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 55
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 55
- 229940028334 follicle stimulating hormone Drugs 0.000 description 55
- 230000008021 deposition Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 241000282887 Suidae Species 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 102000008175 FSH Receptors Human genes 0.000 description 2
- 108010060374 FSH Receptors Proteins 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000020997 lean meat Nutrition 0.000 description 2
- 150000002669 lysines Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UCIYCBSJBQGDGM-LPEHRKFASA-N Ala-Arg-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N UCIYCBSJBQGDGM-LPEHRKFASA-N 0.000 description 1
- PHJPKNUWWHRAOC-PEFMBERDSA-N Asn-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PHJPKNUWWHRAOC-PEFMBERDSA-N 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种FSH抗原及其制备方法以及含有该抗原的FSH疫苗。该疫苗包括偶合有载体蛋白的FSH抗原以及佐剂；FSH抗原的氨基酸序列如SEQ ID NO.1所示，其中第4位和/或第17位氨基酸作为偶联位点与载体蛋白偶联。本发明使FSH抗原及疫苗的制备由不可行变为切实可行；同时，制备得到的FSH抗原/疫苗高效、效果稳定、成本低廉，能够进行大规模商业化生产。
Description
技术领域
本发明属于疫苗制备技术领域，具体涉及一种FSH抗原及其制备方法以及含有该抗原的FSH疫苗。
背景技术
传统生猪养殖过程中，均需对猪进行外科去势。然而，外科去势后猪体脂沉积显著增加，通常体脂含量比完整公猪多5％，且背部脂肪中含有更多的不饱和脂肪酸。脂肪过度沉积不仅降低猪肉品质及经济价值，增加养猪生产成本，同时也对消费者的健康带来不利影响。同样，绝经期妇女脂肪特别是腹腔脂肪沉积显著增加，从而导致肥胖症、脂肪肝、高血压、糖尿病等疾病。近年来研究发现，猪去势或是妇女绝经后脂肪沉积增加均与体内因性腺功能衰退而导致的促卵泡激素(FSH)分泌增加有关。因此，开发和制备一种高效的FSH抗原或疫苗，可有效抑制猪去势或妇女绝经后的肥胖症，及妇女绝经后由肥胖症引起的疾病，具有重大的应用前景。然而，FSH激素分子量大，抗原制备难度大，成本高，目前尚无一种可商业化应用的FSH抗原或疫苗。
发明内容
针对现有技术中的上述不足，本发明提供一种FSH抗原及其制备方法以及含有该抗原的FSH疫苗，使FSH抗原及疫苗的制备由不可行变为切实可行；同时，制备得到的FSH抗原/疫苗高效、效果稳定、成本低廉，能够进行大规模商业化生产。
为实现上述目的，本发明解决其技术问题所采用的技术方案是：
一种FSH疫苗，包括偶合有载体蛋白的FSH抗原以及佐剂；FSH抗原的氨基酸序列如SEQ ID NO.1所示，其中第4位和/或第17位氨基酸作为偶联位点与载体蛋白偶联。
进一步地，氨基酸序列中的第4位和第17位氨基酸侧链氨基均作为偶联位点与载体蛋白偶联。
进一步地，氨基酸序列中的第4位和第17位氨基酸为赖氨酸。
进一步地，载体蛋白可为卵清蛋白、钥孔戚血蓝蛋白、破伤风类毒素、牛血清白蛋白。
进一步地，佐剂为商业化的兽用或人用佐剂。
进一步地，佐剂为Specol。
上述FSH抗原的制备方法，包括以下步骤：
(1)以CTC Resin树脂为原料，采用基于Fmoc的固相多肽合成法合成氨基酸序列如SEQ ID NO.1所示的FSH13a-T寡肽，且以其中的第4位和/或第17 位的氨基酸作为偶联位点；并使用氨基(-NH2)保护基团N-1-(4,4-二甲苯-2,6- 二氧环亚己基)乙基(Dde)将FSH13a-T多寡链中第13位和26位赖氨酸(Lys) 侧链-NH2保护起来(该步具体操作为：在耦合氨基酸中的第13和26位赖氨酸时，选择性使用带半永久性-NH2保护基团的赖氨酸-Lys(Dde))；而寡肽链中第 4位和17位赖氨酸(Lys)侧链-NH2则不保护，以作后面寡肽与载体蛋白进行偶联的偶联位点；由此，制备得到的FSH13a-T寡肽的具体序列如下：
Fmoc-Leu-Val-Tyr-Lys-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde)-Leu-Val-T yr-Lys-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde)-COOH；
(2)将纯化后的FSH13a-T寡肽与载体蛋白以重量比为1～2:1～2的比例混合溶解，然后在缩合剂的作用下，使FSH13a-T寡肽与载体蛋白偶联；偶联后的序列为：
Fmoc--Leu-Val-Tyr-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde) -Leu-Val-Tyr-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde)-COOH；
(3)以步骤(2)所得偶联物为原料，使用2％的水合肼/DMF脱除Dde，然后用异丙醇沉降，过滤，固体用水洗涤，干燥，最终经反相高效液相纯化，获得产物，其具体氨基序列如下：
NH2-Leu-Val-Tyr-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys-Leu-Val-Ty r-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys-COOH。
进一步地，步骤(2)中缩合剂为EDC。
进一步地，步骤(2)中FSH13a-T寡肽与载体蛋白偶联之前，采用氨基保护基团对寡肽氨基酸序列中的第13位和第26位氨基酸侧链氨基进行保护。
进一步地，氨基保护基团为N-1-(4,4-二甲苯-2,6-二氧环亚己基)乙基。
上述方法制备得到的FSH抗原，该FSH抗原的氨基酸序列如SEQ ID NO.1 所示，其中第4位和/或第17位氨基酸作为偶联位点与载体蛋白偶联。
本发明机理为：将FSH疫疫苗主动免疫外科去势动物(如公猪)或绝经期妇女，刺激动物或/人免疫系统产生抗FSH抗体，该抗体特异性与动物或/人内源性FSH结合，从而阻断内源性FSH与其受体结合，使FSH失去促进脂肪沉积的生理作用，从而达到抑制或降低脂肪沉积的效果。
本发明的有益效果为：
本发明中合成的FSH13a-T寡肽成本低，效果稳定；同时合成FSH13a串联体，并进一步与大分子蛋白OVA偶联，使其获得抗原免疫原性，从而真正成为 FSH抗原。该技术方案使FSH抗原及疫苗制备切实可行；且FSH抗原/疫苗生产质量高度可控、效果稳定，成本低廉。
附图说明
图1为去势小鼠脂肪沉积变化量检测图，FSH疫苗显著抑制去势小鼠脂肪沉积；
图2为去势公猪脂肪沉积变化量检测图，FSH疫苗显著抑制去势公猪脂肪沉积。
具体实施方式
下面对本发明的具体实施方式进行描述，以便于本技术领域的技术人员理解本发明，但应该清楚，本发明不限于具体实施方式的范围，对本技术领域的普通技术人员来讲，只要各种变化在所附的权利要求限定和确定的本发明的精神和范围内，这些变化是显而易见的，一切利用本发明构思的发明创造均在保护之列。
实施例1 FSH抗原及疫苗的制备
1、制备FSH抗原
(1)以CTC Resin树脂为原料，采用基于Fmoc的固相多肽合成法合成如 SEQ IDNO.1所示的氨基酸序列，且以其中的第4位和/或第17位的氨基酸作为偶联位点；具体序列如下：
NH2-Leu-Val-Tyr-Lys-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys-Leu-Val-Tyr-Lys- Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys-COOH；
然后使用氨基(-NH2)保护基团N-1-(4,4-二甲苯-2,6-二氧环亚己基)乙基 (Dde)将FSH13a-T寡肽中第13位和26位的赖氨酸(Lys)侧链-NH2保护起来，而寡肽链中第4位和17位赖氨酸(Lys)侧链-NH2则不保护，以作后面寡肽与载体蛋白进行偶联的偶联位点；使得在耦合氨基酸中第13和26位赖氨酸时，选择性使用带半永久性-NH2保护基团的赖氨酸-Lys(Dde)；由此，制备得到的FSH13a-T寡肽的具体序列如下：
Fmoc-Leu-Val-Tyr-Lys-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde)-Leu-Val-T yr-Lys-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde)-COOH；
(2)采用高效液相色谱对FSH13a-T寡肽进行纯化，然后将纯化后的FSH13a-T寡肽与载体蛋白以重量比为1～2:1～2的比例混合溶解，然后在缩合剂的作用下，使FSH13a-T寡肽与载体蛋白偶联；偶联后的序列为：
Fmoc--Leu-Val-Tyr-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde)-Le u-Val-Tyr-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys(Dde)-COOH；
(3)以步骤(2)所得偶联物为原料，使用质量分数为偶联物重量2％的水合肼/DMF脱除Dde，然后用异丙醇沉降，过滤，固体用水洗涤，干燥，最终经反透析纯化，获得FSH抗原，其具体氨基序列如下：
NH2-Leu-Val-Tyr-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys-Leu-Val-Ty r-Lys(OVA)-Asp-Pro-Ala-Arg-Pro-Asn-Ile-Gln-Lys-COOH。(SEQ ID NO.1)
2、制备FSH疫苗
采用Specol佐剂乳化制备得到的FSH抗原，制得FSH疫苗。
实施例2小鼠模型动物实验
1、设置A、B、C三组小鼠(mouse)为模型，每组均包括C57/6J雌性小鼠；在小鼠6周龄时，对B、C两组小鼠进行手术去势，A组不做处理。
2、在7周龄时，B组去势小鼠主动免疫FSH疫苗(OVX+FSH vaccine；腿部肌肉注射0.5mL疫苗，含200μg FSH抗原)，A组(Control)和C组(OVX) 分别注射不含FSH抗原的乳化剂，以作为对照。
B组小鼠在首次注射4周和12周后分别再次注射FSH疫苗一次，免疫方法和注射剂量与首次等同；A组和C组小鼠在首次注射4周和12周后分别再次注射不含FSH抗原的乳化剂。然后在8周后处死所有小鼠，试验期间称体重、采集血液测定血清FSH抗体含量。处死小鼠时，称量小鼠腹腔脂肪重量，测定血脂含量。采集腹腔内脏脂肪测定FSH调控脂肪沉积信号通路相关分子基因蛋白表达变化。其检测结果见图1。
如图1所示，本FSH疫苗给小鼠注射后，能刺激小鼠机体产生显著的抗体反应(图1A)；与完整小鼠(control)相比，小鼠去势后，体脂肪沉积显著增加 (图1B和图1C)；而小鼠去势的同时注射FSH疫苗，其体脂沉积显著降低，与去势小鼠(OVX)相比其体脂沉积降低了46.3％(图1B和图1C)。进一步发现，去势小鼠注射FSH疫苗显著降低脂其肪组织FSH受体(FSHR)表达，继而抑制去势小鼠脂肪组织脂肪合成关键基因PPARγ及PPARγ靶基因FAS、ACC 及LPL的表达，从而抑制脂肪合成和沉积(图1D)。该结果证实：该FSH疫苗能显著抑制去势动物脂肪沉积。图1A和图1C中*:P<0.05；**:P<0.01；图1D 中不同小写a,b,c字母表示组间差异显著(P<0.05)；图1A箭头表示FSH疫苗注射时间点。
实施例3去势公猪脂肪沉积的效果评价
设置a、b、c三组实验，每组公猪12只，其中b、c两组的仔公猪出生一周内进行手术去势，a组不做处理；
b组去势公猪10周龄时主动免疫FSH疫苗(颈部肌肉注射2mL FSH疫苗，含200μgFSH抗原)，在首次注射4周及8周后分别再次注射FSH疫苗，免疫方法和注射剂量与首次相同。a组去势公猪及c组公猪分别注射不含FSH抗原的乳化剂，以作为对照，然后检测各组公猪中脂肪沉积结果，其检测结果见图2。
如图2所示，与完整仔公猪(control)相比，去势后的仔公猪的背膘厚度(图 2A)及脂肪沉(图2B)积显著增加而胴体瘦肉率显著降低(图2C)；而仔公猪去势的同时注射FSH疫苗，其背膘厚度及脂肪沉积显著降低(图2A和图2B)而瘦肉率显著增加(图2C)。该结果证实：该FSH疫苗能显著抑制去势公猪脂肪沉积。a,b,c不同字母表示组间差异显著(P<0.05)。
序列表
<110> 四川农业大学
<120> 一种FSH抗原及其制备方法以及含有该抗原的FSH疫苗
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 26
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Leu Val Tyr Lys Asp Pro Ala Arg Pro Asn Ile Gln Lys Leu Val Tyr
1 5 10 15
Lys Asp Pro Ala Arg Pro Asn Ile Gln Lys
20 25
Claims (9)
1.一种FSH疫苗，其特征在于，包括偶合有载体蛋白的FSH抗原以及佐剂；所述FSH抗原的氨基酸序列如SEQ ID NO.1所示，其中第4位和/或第17位氨基酸作为偶联位点与载体蛋白偶联。
2.根据权利要求1所述的FSH疫苗，其特征在于，所述氨基酸序列中的第4位和第17位氨基酸侧链氨基均作为偶联位点与载体蛋白偶联。
3.根据权利要求1所述的FSH疫苗，其特征在于，所述载体蛋白为卵清蛋白、钥孔戚血蓝蛋白、破伤风类毒素或牛血清白蛋白。
4.一种权利要求1所述的FSH抗原的制备方法，其特征在于，包括以下步骤：
（1）以CTC树脂为原料，采用固相多肽合成法合成氨基酸序列如SEQ ID NO.1所示的FSH13a-T寡肽，且以其中的第4位和/或第17位的氨基酸作为偶联位点；
（2）将纯化后的FSH13a-T寡肽与载体蛋白以重量比为1~2:1~2的比例混合溶解，然后在缩合剂的作用下，使FSH13a-T寡肽与载体蛋白偶联。
5.根据权利要求4所述的FSH抗原的制备方法，其特征在于，步骤（1）中制备FSH13a-T寡肽时，还包括采用氨基保护基团对寡肽氨基酸序列中的第13位和第26位氨基酸侧链氨基进行保护。
6.根据权利要求5所述的FSH抗原的制备方法，其特征在于，所述氨基保护基团为N-1-(4,4-二甲苯-2,6-二氧环亚己基）乙基。
7.根据权利要求4所述的FSH抗原的制备方法，其特征在于，步骤（2）中所述缩合剂为1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐。
8.根据权利要求4所述的FSH抗原的制备方法，其特征在于，还包括偶联完成后，以偶联物为原料，使用2%的水合肼/DMF脱除用于保护第13位和第26位氨基酸侧链氨基的N-1-(4,4-二甲苯-2,6-二氧环亚己基）乙基，然后再用异丙醇沉降，过滤洗涤干燥后纯化，获得纯化后的FSH抗原。
9.权利要求4~8任一项所述方法制备得到的FSH抗原，其特征在于，所述FSH抗原的氨基酸序列如SEQ ID NO.1所示，其中第4位和/或第17位氨基酸作为偶联位点与载体蛋白偶联。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911023197.XA CN110694056B (zh) | 2019-10-25 | 2019-10-25 | 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911023197.XA CN110694056B (zh) | 2019-10-25 | 2019-10-25 | 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110694056A CN110694056A (zh) | 2020-01-17 |
| CN110694056B true CN110694056B (zh) | 2023-05-05 |
Family
ID=69202353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911023197.XA Active CN110694056B (zh) | 2019-10-25 | 2019-10-25 | 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110694056B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116375844B (zh) * | 2023-02-22 | 2024-03-29 | 四川农业大学 | 一种抑制素抗原肽及其疫苗和制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493052A (zh) * | 2001-02-19 | 2004-04-28 | Ĭ��ר������˾ | 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途 |
| CN106047820A (zh) * | 2016-08-22 | 2016-10-26 | 成都大熊猫繁育研究基地 | 大熊猫促卵泡素β亚基单克隆抗体的制备及应用 |
| CN106986923A (zh) * | 2017-04-10 | 2017-07-28 | 新疆农垦科学院 | GnRH抗原及其在主动免疫对公牛的去势效果及肉品质影响中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11034761B2 (en) * | 2016-07-29 | 2021-06-15 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for reducing adiposity by inhibiting FSH/FSHR |
-
2019
- 2019-10-25 CN CN201911023197.XA patent/CN110694056B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493052A (zh) * | 2001-02-19 | 2004-04-28 | Ĭ��ר������˾ | 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途 |
| CN106047820A (zh) * | 2016-08-22 | 2016-10-26 | 成都大熊猫繁育研究基地 | 大熊猫促卵泡素β亚基单克隆抗体的制备及应用 |
| CN106986923A (zh) * | 2017-04-10 | 2017-07-28 | 新疆农垦科学院 | GnRH抗原及其在主动免疫对公牛的去势效果及肉品质影响中的应用 |
Non-Patent Citations (9)
| Title |
|---|
| A novel follicle-stimulating hormone vaccine for controlling fat accumulation;Xingfa Han et al.;《Theriogenology》;20200305;第103-111页 * |
| Blocking FSH induces thermogenic adipose tissue and reduces body fat;Peng Liu et al.;《Nature》;20170601;第107-112页 * |
| Epitope-specific monoclonal antibodies to FSHβ increase bone mass;Yaoting Ji et al.;《Proc Natl Acad Sci U S A》;20180227;第115卷(第9期);第2193页左栏第2段 右栏第3段，第2194页左栏第1，2段，第2193页左栏第2段-右栏第1段，图1 * |
| GnRH主动免疫对动物生殖及生产性能的影响及其作用机制研究;韩兴发;《中国博士学位论文全文数据库 农业科技辑》;20200115;第D050-78页 * |
| 冯新港主编.抗原表位疫苗.《免疫信息学原理及其应用》.上海科学技术出版社,2009, * |
| 冯维祺等编著.脂肪的发育.《肉羊高效益饲养技术》.金盾出版社,1995, * |
| 张雄鹰主编.表位疫苗-疫苗研制的新策略.《微生物学与免疫学》.中国医药科技出版社,2016, * |
| 表位疫苗研究进展;赵德 等;《动物医学进展》;20120220;第102-106页 * |
| 陈春良，陆振清主编.小母猪不去势和提高胴体瘦肉率.《新编瘦肉猪饲养手册》.上海科学技术文献出版社,1997, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110694056A (zh) | 2020-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0708656B1 (en) | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines | |
| KR102166545B1 (ko) | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 | |
| JP3177246B2 (ja) | 未去勢のオスの家畜に対する抗ｌｈｒｈ免疫方法と、そのためのペプチド | |
| KR100335320B1 (ko) | 황체호르몬방출호르몬에대한향상된펩티드,면역원성조성물및백신또는의학용제제,동물을면역시키는방법,및황체호르몬방출호르몬직렬반복펩티드의유사체및백신으로서이들의용도 | |
| CN110694056B (zh) | 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 | |
| CA1330420C (en) | Compositions containing growth hormone peptide fragments | |
| AU2021102671A4 (en) | Preparation Method for One Type FSH Antigen and FSH Vaccine, Containing This Type of Antigen | |
| AU630591B2 (en) | Growth hormone related peptide | |
| NZ227073A (en) | Peptide structures and synthetic immunogens and their use in fertility control | |
| CN100522994C (zh) | GnRH-I和GnRH-II之间的区分 | |
| EP0406316B1 (en) | Peptides derived from Foot and mouth disease virus | |
| IE67318B1 (en) | Biologically active molecules | |
| JP2002518033A (ja) | 農場動物の成長促進のための合成ソマトスタチン免疫原 | |
| CN116375844B (zh) | 一种抑制素抗原肽及其疫苗和制备方法 | |
| CN108047328A (zh) | 一种GnRH多肽抗原及其用于制备去势疫苗的应用 | |
| US5401829A (en) | Biologically active molecules | |
| AU643444B2 (en) | SRIF-related peptides and uses thereof | |
| BROWN et al. | Synthetic peptides in animal health | |
| Hasegawa et al. | Evaluation of the contraceptive potential of recombinant proteins and synthetic peptides of zona pellucida (ZP) | |
| MXPA99005693A (en) | Vaccine for the reversible immunocastration of mammals | |
| CZ289521B6 (cs) | Anti-LHRH vakcinační souprava pro výrobu masa se zlepąenými organoleptickými vlastnostmi, získávaného z nevykastrovaných samců domácích zvířat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |